Re: Comments on Proposed Decision Memorandum (CAG-00065R2) Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer
|
|
- Abraham Gilmore
- 5 years ago
- Views:
Transcription
1 1300 North 17 th Street Suite 900 Arlington, Virginia Tel: Fax: October 15, 2015 Tamara Syrek Jensen, Esq. Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services Department of Health and Human Services 7500 Security Boulevard Baltimore, MD Re: Comments on Proposed Decision Memorandum (CAG-00065R2) Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer Dear Director Syrek Jensen: The Medical Imaging & Technology Alliance (MITA) appreciates this opportunity to submit comments to express its serious concerns with the referenced proposed decision memorandum on the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) Section B. 1 MITA contends that the published registry and other evidence submitted by the National Oncologic PET Registry (NOPR) Working Group in its reconsideration request for this coverage with evidence development (CED) decision is more than sufficient. It clearly shows the important benefits of NaF-18 positron emission tomography (NaF PET) scans in managing Medicare beneficiaries with bone metastases, and to support coverage without the data collection prerequisite. MITA therefore believes CMS should not finalize its proposed decision and instead: Remove the requirement for prospective data collection for coverage of NaF PET for oncologic indications; and Delegate to the local Medicare Administrative Contractors (MACs) the determination of coverage for non-oncologic indications. This approach would be similar to the one taken by CMS in its recent reconsideration of the CED for fluorodeoxyglucose positron emission tomography (FDG PET) for oncologic indications. 2 1 See Proposed Decision Memorandum on NaF-18 PET to Identify Bone Metastasis of Cancer (Sept. 16, 2015), available at 2 See Decision Memorandum on FDG PET for Solid Tumors (June 11, 2013), available at
2 If CMS declines to remove the data requirements and extend coverage an outcome we would have difficulty understanding we urge the agency to continue the CED until such time as the additional evidence sought by CMS can be reviewed and submitted for publication. Whereas CMS suggests a 12- month period would be sufficient to allow a confirmatory analysis of changes in patient management, MITA believes the continuation of the current CED for a more realistic time period of no fewer than eighteen months be applied. Only in this way can appropriate beneficiary access to an important diagnostic tool be preserved. About MITA MITA is the leading industry association representing medical imaging, radiation therapy, and radiopharmaceutical manufacturers. We have a long-standing and documented history of supporting appropriate use of these technologies for the early detection, diagnosis, staging, therapy monitoring, and surveillance of many diseases including oncology, neurology and cardiology applications of PET imaging and most recently low-dose CT for lung cancer screening. Because the proposed decision, if finalized, would eliminate an appropriate use for appropriate patients, MITA members strongly urge CMS to revisit the submitted data along with any additional data, and not finalize its proposed decision. MITA Comments I. EVIDENCE ON NAF-18 PET SCANS TO IDENTIFY BONE METASTASIS OF CANCER MEETS THE MEDICARE REASONABLE AND NECESSARY UNDER 1862(A)(1)(A) A. Improved Patient Management Section 1862(a)(1)(A) of the Social Security Act articulates the standard for withholding coverage if a diagnostic test is not reasonable and necessary to diagnose... an illness or injury. The proposed decision memo concludes that the appropriate measure of whether NaF PET is reasonable and necessary for purposes of meeting the 1862(a)(1)(A) standard is whether it affects health outcomes through changes in disease management brought about by physician actions taken in response to test results. 3 The proposed decision memo goes on to state that [s]uch actions may include decisions to treat or withhold treatment, to choose one treatment modality over another, or to choose a different dose or duration of the treatment. 4 We believe this is precisely what the NOPR data show. The current CED for NaF-18 Positron Emission Tomography (NaF PET) was developed to inform the initial antitumor treatment strategy or to guide subsequent antitumor treatment strategy after completion of the initial treatment. 5 In the proposed decision memo, CMS states that to evaluate whether continued collection was needed, the agency evaluated the presented data and other published evidence for evidence demonstrating how the treating physician uses the result of a NaF-18 PET imaging test for cancer metastasis to bone in whom bone metastases are strongly suspected based on clinical symptoms or 3 CMS derives this standard from its regulation at 42 C.F.R (a), which refers to the requirement that the ordering physician must be the treating physician and must use the results in managing the beneficiary s specific condition. This regulation, therefore, defines only whether a particular diagnostic test should be covered for a particular individual whose physician orders the test (that is, it must be the physician actually caring for the patient and the test results must in fact be used by this physician). Although MITA does not agree that this is the appropriate source for deriving the standard for evaluating evidence for an NCD, we accept the standard CMS identifies that a diagnostic test should provide information that has the potential to influence the course of treatment. 4 CMS also observes in its proposed decision memorandum that [a]s a diagnostic test, NaF-18 PET would not be expected to directly change health outcomes. MITA agrees. 5 Medicare National Coverage Determinations Manual (CMS Pub ), B. 2
3 the results of other diagnostic studies. 6 The published studies on the NOPR data address the treating physicians uses of the diagnostic information in disease management. Since its inception in 2011, the NOPR NaF PET Registry has collected data for over 27,000 patients at 1,000 different PET facilities nationwide. Peer-reviewed published studies address the registry data, which include comparisons of management plans before and after NaF PET were performed on patients receiving systemic therapy for metastatic cancer. 7,8,9 This included evaluations of options to treat or withhold treatment or to choose a different dose or duration of treatment by continuing, modifying, switching or stopping all therapy. One published article reported on the analysis set of 2,217 of the patients 65 years or older receiving systemic therapy, such as chemotherapy or immunotherapy. The study s 2,839 scans had an overall post-naf PET change in intended management of 40% (42% for prostate, 39% for breast and 35% for all other cancers). Not only were the treating physicians able to use the information to plan a continuation of current therapy, a switching of therapy, modification of doses or schedule and stopping all therapy, but additionally, the referring physician judged the post-pet prognosis to be better, worse or unchanged from the pre-pet prognosis. 10 MITA believes the published NOPR data provide evidence that CMS seeks on the changes in management due to test findings. Nonetheless, CMS has rejected this data and requested confirmatory analysis, finding that the data provided by NOPR and others only reported on intended management changes, but did not confirm that actual change in management occurred. This standard is inconsistent with CMS s articulated standard for reconsidering the CED for Fluorodeoxyglucose (FDG) PET for solid tumors. There, CMS was presented with similar evidence that the FDG PET had a significant effect on the intended treatment of various solid tumors, but nonetheless concluded that the information was sufficient to support[ ] the use of FDG PET as reasonable and necessary in the management of those tumors. For example, CMS found that the FDG PET had a larger effect on intended treatment for those with primary brain tumors than those in the overall registry population, and found this evidence sufficient to conclude the use of the FDG PET as reasonable and necessary for the management of recurrent primary brain tumors. Similarly, CMS found that physicians managing treatment of patients with prostate cancer would change their intended therapy in about 40% of instances after use of the FDG PET. MITA therefore requests that CMS similarly end CED for NaF-18 PET and cover the NaF-18 PET under 1862(a)(1)(A). B. Identifies Bone Metastasis of Cancer More Precisely than Alternative Tests Physicians participating in the NOPR study indicate that without the NaF PET, other interventions would be used. Indeed, these tests have some clinical disadvantages, yet are covered without the barrier of a CED. The clinical data for prostate cancer cases show that the NaF technology may be more advantageous than alternative bone scanning (using Tc-99 diphophonates) because of its superior image 6 Proposed Decision at 3. 7 Hillner BE, et al. 18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry. J Nucl Med 2015, 56: Hillner BE, et al. Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. J Nucl Med 201; 55: Hillner BE et al. Impact of 18F-fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry. J Nucl Med 2014; 55: See Hillner BE, et al., supra, footnote 7 at pp See also id. at 227 (The NOPR data results suggest that NaF PET leads to alterations in planned treatment in a substantial fraction of patients with osseous metastatic disease. ) 3
4 quality, and because it emits a lower radiation dose. 11 NaF PET has been shown to provide higher sensitivity and specificity than bone scintigraphy for the detection of osseous metastases in men with prostate cancer. 12 In addition to these advantages, Medicare beneficiaries across the country now are able to access this important technology because the infrastructure of cyclotrons and PET scanners is sufficient to reach all areas of the country. II. MITA URGES CMS TO CONTINUE CED COVERAGE DURING ANY FURTHER DATA GATHERING AND REVIEWS CMS covers NaF PET scans to identify bone metastasis of cancer when the service is performed through the CMS-approved registry, with a CMS-approved protocol. Over 1000 facilities have participated so far in the NaF PET study. CMS now requests additional analysis to answer the following question: Does the addition of NaF-18 PET imaging lead to: a change in patient management to more appropriate palliative care; a change in patient management to more appropriate curative care; improved quality of life; or improved survival? To allow confirmatory evidence to be performed, CMS proposes to continue the requirement for CED under Section 1862(a)(1)(E) for 12 months after CMS s final decision on this reconsideration. To the extent CMS s final decision does not continue coverage for NaF PET, MITA has serious concerns that 12 months will provide insufficient time for collection, analysis and publication of confirmatory data requested by CMS. A minimum of 18 months from the final decision is needed to obtain the necessary data, draft the requisite analysis, submit for publication, and complete the new reconsideration process. Moreover, we understand that conducting such a study will depend to a large degree on the ability to obtain expedited access to the requisite Medicare claims data. This would most likely lead to a gap in coverage for Medicare beneficiaries with devastating diagnoses. MITA therefore encourages extension of the CED for a minimum of 18 months from the date the final decision. Moreover, this extension is consistent with CMS s CED guidance. CMS s most recent CED Guidance document notes that a CED cycle is only considered completed when CMS completes a reconsideration of the CED coverage decision, and removes the requirement for study participation as a condition of coverage. Because CMS has requested further confirmatory analysis, and because such analysis will require further data gathering through extended study participation, CMS may extend the CED for longer than 12 months. MITA encourages and supports continuing the current CED so as to avoid a coverage gap for Medicare beneficiaries. CONCLUSION MITA has and continues to support the NOPR Working Group s efforts to end the data collection requirements under CED for oncologic indications using NaF PET. We believe the clinical evidence more than adequately shows the benefits of patient management with NaF PET. For the reasons stated, we therefore urge CMS to re-evaluate the evidence and revise the current CED to extend coverage for initial and subsequent imaging for oncologic indications. We also support the reconsideration request to 11 Jadvar H, Molecular Imaging of Prostate Cancer with PET. J Nucl Med 2013;54: Id. 4
5 allow Medicare Administrative Contractor discretion for non-oncologic indications to evaluate benign bone disease using NaF PET imaging. This would be consistent with the approach taken by CMS for FDG PET. To the extent the agency declines to remove the CED data requirements, we urge CMS to continue coverage under the CED until such time as additional evidence can be collected and reviewed, and the third reconsideration process can be completed, a period of no fewer than eighteen months. * * * * MITA would be pleased to answer any questions you might have about these comments or if we can be of further assistance. Please do not hesitate to contact me at (703) Sincerely, Terri Wilson, MBA, BS, CNMT Director, Molecular Imaging & PET, MITA 5
World Molecular Imaging Society (WMIS) Comment on Proposed Decision Memorandum for Positron Emission Tomography (CAG-00065R2)
January 11, 2013 Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services 7500 Security Blvd Baltimore, MD 21244 By Online Submission RE: World Molecular Imaging Society (WMIS) Comment
More informationRe: Proposed Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)
1300 North 17 th Street Suite 1752 Arlington, Virginia 22209 Tel: 703.841.3200 Fax: 703.841.3392 www.medicalimaging.org July 26, 2013 By electronic mail Louis Jacques, MD Director Coverage and Analysis
More informationJoint Comments on Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer (CAG-00065R1)
July 2, 2009 Tamara Syrek Jensen, J.D. Acting Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services 7500 Security Blvd., Mail Stop C1-09-06 Baltimore, MD 21244 Re: Joint Comments
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationJuly 20, Via Electronic Delivery
July 20, 2012 Louis B. Jacques, MD Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services 7500 Security Blvd Baltimore, MD 21244 Via Electronic Delivery RE: National Oncologic PET
More informationNational Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms
Form (NOPR) F-18 Fluoride PET Case Report Forms Version Date Patient Information Sheet 06/17/10 (Spanish translation available at: http://www.cancerpetregistry.org/pdf/patient_info_spanish.pdf) Interpreting
More informationRE: Coverage of low-dose Computed Tomography (LDCT) lung cancer screening in Independent Diagnostic Testing Facilities (IDTFs)
May 11, 2018 Tamara Syrek Jensen, JD Director, Coverage and Analysis Group Department of Health and Human Services Center for Medicare and Medicaid Services 7500 Security Boulevard, Mail Stop S3-02-01
More informationThe IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases
The IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases The International Atomic Energy Agency works to improve human health through the use of nuclear techniques. This includes
More informationPET/CT Value: Rocky Mountain Cancer Centers
PET/CT Value: Rocky Mountain Cancer Centers Glenn Balasky Executive Director Rocky Mountain Cancer Centers glenn.balasky@usoncology.com CANM/CAMRT Joint Conference March 22, 2018 Vancouver, British Columbia
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationOncologists have many options for tracking a patient s response
F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry Bruce E. Hillner 1, Barry A. Siegel 2, Lucy Hanna 3, Fenghai Duan 3, Bruce Quinn
More informationRE: Proposed National Coverage Decision (NCD) Memorandum for Percutaneous Left Atrial Appendage Closure (LAAC) Therapy (CAG-00445N)
December 10, 2015 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 RE: Proposed National Coverage Decision
More informationTransmittal 166 Date: April 18, 2014
S anual System Pub 100-03 edicare National overage Determinations Department of Health & Human Services (DHHS) enters for edicare & edicaid Services (S) Transmittal 166 Date: April 18, 2014 hange Request
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationPMC Statement of Neutrality
March 17, 2019 Tamara Syrek Jensen, J.D. Director, Coverage & Analysis Group Mailstop S3-02-01 7500 Security Blvd. Baltimore, MD 21244 Sent electronically RE: Proposed Decision Memo for Chimeric Antigen
More informationCMS Issues New Draft Guidance on Coverage with Evidence Development Policy for National Coverage Determinations
December 6, 2012 CMS Issues New Draft Guidance on Coverage with Evidence Development Policy for National Coverage Determinations For more information, contact: Seth H. Lundy +1 202 626 2924 slundy@kslaw.com
More informationCriteria USPSTF CMS. Frequency Annual screening Annual screening. No signs or symptoms of lung cancer
Lung Cancer Screening Guidelines with low- dose computed tomography (LDCT): USPSTF and CMS February 6, 2015 Kentucky Cancer Consortium and Kentucky LEADS Component 3 Jennifer Redmond Knight, DrPH, jredknight@kycancerc.org
More informationCANCER LEADERSHIP COUNCIL
CANCER LEADERSHIP COUNCIL A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS ADDRESSING PUBLIC POLICY ISSUES IN CANCER November 17, 2015 Andy Slavitt Acting Administrator Centers for Medicare
More informationJanuary 17, Sent electronically
January 17, 2018 Tamara Syrek Jensen, J.D. Director, Coverage & Analysis Group Mailstop S3-02-01 7500 Security Blvd. Baltimore, MD 21244 Sent electronically RE: Proposed Medicare Coverage Decision Memorandum
More informationRE: Proposed Decision Memo for Screening for Hepatitis C Virus (HCV) in Adults (CAG-00436N)
April 2, 2014 Tamara Syrek Jensen, JD Acting Director Coverage and Analysis Group Center for Clinical Standards and Quality Centers for Medicare and Medicaid Services U.S. Department of Health and Human
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationSeptember 6, Dear Centers for Medicare & Medicaid Services,
September 6, 2016 Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1631-P Mail Stop C4-26-05 7500 Security Boulevard Baltimore, MD 21244-1850 Re: Revisions
More informationExecutive Summary. Positron emission tomography (PET and PET/CT) in malignant lymphoma 1. IQWiG Reports Commission No. D06-01A
IQWiG Reports Commission No. D06-01A Positron emission tomography (PET and PET/CT) in malignant lymphoma 1 Executive Summary 1 Translation of the executive summary of the final report Positronenemissionstomographie
More informationProstate Cancer Basics: Background Information for Outreach Activities with Oncologists, Urologists and Surgeons
Prostate Cancer Basics: Background Information for Outreach Activities with Oncologists, Urologists and Surgeons Legal Disclaimer These materials were prepared in good faith by MITA as a service to the
More information1-Appropriate Use Criteria for Advanced Diagnostic Imaging Services
The Honorable Seema Verma, Administrator Centers for Medicare and Medicaid Services Attention: CMS 1676 P P.O. Box 8016 Baltimore, MD 21244 1850 Dear Administrator Verma: September 10, 2017 On behalf of
More informationEvaluation of Cancer Outcomes Barwon South West Registry
Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details
More informationPositron emission tomography Medicare Services Advisory Committee
Positron emission tomography Medicare Services Advisory Committee Authors' objectives To assess the effectiveness of positron emission tomography (PET), the report addressed the following (truncated) six
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information
More informationEXCERPTED FROM REHABILITATION ASSOCIATION OF VIRGINIA, INC. V. KOZLOWSKI, ET AL., 42 F. 3D 1444,1450 (4 TH CIR. 1994)
There can be no doubt but that the statutes and provisions in question, involving the financing of Medicare, are among the most completely impenetrable texts within human experience... one approaches [them]
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationTITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer
AD Award Number: W81XWH-10-1-0824 TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer PRINCIPAL INVESTIGATOR: Joanne Mortimer, M.D. CONTRACTING ORGANIZATION: City of
More informationMedicare Program; Reconciling National Coverage Determinations on Positron. Emission Tomography (PET) Neuroimaging for Dementia
This document is scheduled to be published in the Federal Register on 04/11/2018 and available online at https://federalregister.gov/d/2018-07410, and on FDsys.gov BILLING CODE 4120-01-P DEPARTMENT OF
More informationHybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD
Hybrid Imaging SPECT/CT PET/CT PET/MRI SNMMI Southwest Chapter 2014 Aaron C. Jessop, MD Assistant Professor, Department of Nuclear Medicine UT MD Anderson Cancer Center, Houston, Texas Complimentary role
More informationWake Radiology integrates PET CT and radiation oncology. New facility offers patients new conveniences and consolidates physicians services
Triangle Edition March 2009 VOL. 11, NO. 2 Wake Radiology integrates PET CT and radiation oncology New facility offers patients new conveniences and consolidates physicians services Wake Radiology Nuclear
More informationManaging Denials and Appeals
Managing Denials and Appeals Lack of precertification or authorization Medical necessity Experimental and investigational Requires additional information Non-covered service/medication on the plan benefit
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationNuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationAustin Radiological Association TUMOR GLUCOSE METABOLISM STUDY (F-18-Fluorodeoxyglucose)
Austin Radiological Association TUMOR GLUCOSE METABOLISM STUDY (F-18-Fluorodeoxyglucose) Overview Most cancers take up and metabolize approximately five times as much glucose as normal tissues. F-18-fluorodeoxyglucose
More informationASCO Publishes "Top Five" List of Opportunities to Improve Quality and Value in Cancer Care
Published on ASCO (https://www.asco.org) Home > ASCO Publishes "Top Five" List of Opportunities to Improve Quality and Value in Cancer Care ASCO Publishes "Top Five" List of Opportunities to Improve Quality
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationRe: Orthotics and Prosthetic Services Provided by Occupational Therapists and Physical Therapists under the Medicare Program
July 15, 2010 Peter Budetti, MD, JD Deputy Administrator, Center for Program Integrity Centers for Medicare and Medicaid Services Department of Health and Human Services 200 Independence Avenue, SW Mail
More informationMay 16, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org May 16, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationFIRST COAST SERVICE OPTIONS FLORIDA MEDICARE PART B LOCAL COVERAGE DETERMINATION
FIRST COAST SERVICE OPTIONS FLORIDA MEDICARE PART B LOCAL COVERAGE DETERMINATION CPT/HCPCS Codes 72192 Computed tomography, pelvis; without contrast material 72193 with contrast material(s) 72194 without
More informationThe Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Insurance Coverage For Low Dose CT Lung Screenings with Barbara Wiggin,
More informationPharmacogenomic Testing for Warfarin Response (NCD 90.1)
Policy Number 90.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationPhillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA
ADVANCED PET IMAGING IN PROSTATE CANCER Phillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA PET, positron-emission tomography DISCLAIMER Please note: The views
More informationOncologic Applications of PET Scanning
6.01.26 Oncologic Applications of PET Scanning Section 6.0 Radiology Subsection Effective Date February 15, 2015 Original Policy Date January 26, 2009 Next Review Date December 2015 Description Positron
More informationJune 21, Harry Feliciano, MD, MPH Senior Medical Director Part A Policy Palmetto GBA PO Box (JM) AG-275 Columbia, SC 29202
June 21, 2018 Harry Feliciano, MD, MPH Senior Medical Director Part A Policy Palmetto GBA PO Box 100238 (JM) AG-275 Columbia, SC 29202 Submitted electronically: A.Policy@PalmettoGBA.com RE: Proposed LCD
More informationAssessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose
Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose Poster No.: C-0805 Congress: ECR 2015 Type: Scientific Exhibit Authors: S. Ito, K. Kato,
More informationFIRST COAST SERVICE OPTIONS FLORIDA MEDICARE PART B LOCAL COVERAGE DETERMINATION
FIRST COAST SERVICE OPTIONS FLORIDA MEDICARE PART B LOCAL COVERAGE DETERMINATION CPT/HCPCS Codes 78300 Bone and/or joint imaging; limited area 78305 multiple areas 78306 whole body 78315 three phase study
More informationFIRST COAST SERVICE OPTIONS FLORIDA MEDICARE PART B LOCAL COVERAGE DETERMINATION
FIRST COAST SERVICE OPTIONS FLORIDA MEDICARE PART B LOCAL COVERAGE DETERMINATION CPT/HCPCS Codes 71250 Computed tomography, thorax; without contrast material 71260 with contrast material(s) 71270 without
More informationBone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors
Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors Lars Stegger, Benjamin Noto Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to
More informationYes, the PET-CT report dated April 13 th 2016 was included in the structured summary reviewed by a medical oncologist at Tata Memorial Centre.
May 9 th 2016 Dear Mr. Ramesh Srivastava, Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya is pleased to offer this online consultation
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PET Scanning: Oncologic Applications Page 1 of 88 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Positron Emission Tomography (PET) Scanning: Oncologic Applications
More informationSubject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:
Subject: PET Scan With or Without CT Attenuation Policy Number: MCR: 610 Revision Date(s): MHW Original Effective Date: 11/7/2017 Review Date: DISCLAIMER This Molina Clinical Review (MCR) is intended to
More informationThe AAO- HNS s position statement on Point- of- Care Imaging in Otolaryngology states that the AAO- HNS,
AAO- HNS Statement on Diagnostic Imaging Reimbursement for Otolaryngologist Head and Neck Surgeons (September 2014) The American Academy of Otolaryngology Head and Neck Surgery (AAO- HNS), with approximately
More informationFOR CMS (MEDICARE) MEMBERS ONLY NATIONAL COVERAGE DETERMINATION (NCD) FOR MAGNETIC RESONANCE IMAGING:
National Imaging Associates, Inc. Clinical guidelines BONE MARROW MRI Original Date: July 2008 Page 1 of 5 CPT Codes: 77084 Last Review Date: September 2014 NCD 220.2 MRI Last Effective Date: July 2011
More informationMedicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services US Department of Health and Human Services Attention: CMS-1695-FC P.O. Box 8013, 7500 Security Boulevard Baltimore, MD 21244-1850
More informationBone Metastasis. Patient Management with PET/CT
Bone Metastasis Patient Management with PET/CT Bone Metastasis Patient Management with PET/CT OVERVIEW Bone Metastasis is a process in which cancer cells from the original or primary tumor site break away
More informationJanuary 17, Dear Ms. Syrek Jensen,
January 17, 2018 Tamara Syrek Jensen, JD Director, Coverage & Analysis Group Center for Clinical Standards and Quality Centers for Medicare & Medicaid Services Mailstop S3-02-01 7500 Security Blvd Baltimore,
More informationIngenuity TF PET/CT. Comfort and quality care in one. Your PET/CT scan with Philips Ingenuity TF PET/CT
Ingenuity TF PET/CT Comfort and quality care in one Your PET/CT scan with Philips Ingenuity TF PET/CT What s a PET/CT scan, an A PET/CT scan provides your doctor and medical specialists with valuable information
More informationContractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC B. LCD ID Number: L34834 Status: A-Approved
LCD for Blood Glucose Monitoring in a Skilled Nursing Facility (SNF) (L34834) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12502 Contractor Type: MAC B LCD ID Number: L34834 Status: A-Approved
More information4. On, the Appellant s Request for Hearing was received by the Michigan Administrative Hearing System.
4. On, the Appellant s Request for Hearing was received by the Michigan Administrative Hearing System. CONCLUSIONS OF LAW The Medical Assistance Program is established pursuant to Title XIX of the Social
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationLung Cancer Screening: Current Status
Lung Cancer Screening: Current Status I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of investigational or off-label use of a product
More informationGENERAL COMMENTS. The Task Force Process Should be Fully Open, Balanced and Transparent
December 9, 2013 Submitted Electronically United States Preventive Services Task Force c/o Dr. Robert Cosby Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 RE: USPSTF Draft
More informationRe: Comprehensive Ambulatory Payment Classification Methodology
Tiffany Swygert Director, Division of Outpatient Care Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244-1850 Re: Comprehensive Ambulatory Classification Methodology
More informationTestimony of Robert Egge, Vice President of Public Policy Alzheimer s Association. December 8, 2010
U.S. Senate Special Committee on Aging Until There s A Cure: How to Help Alzheimer s Patients and Families NOW Testimony of Robert Egge, Vice President of Public Policy Alzheimer s Association December
More informationPET FDG *** (cost-effectiveness) FDG-PET (fluorodeoxyglucose-positron emission tomography) PET PET PET/PET-CT PET PET FDG PET FDG PET PET PET
119 PET FDG * *, ** * * *** PET 10 PET 2005 FDG PET FDG FDG 3 PET PET FDG A B C 3 PET 1,591 1,637 914 1 110,262 111,091 134,192 2,583 2,679 2,081 FDG PET PET PET PET ( 45: 119 123, 2008) FDG-PET (fluorodeoxyglucose-positron
More informationImplementation: Public Hearing: Request for Comments (FDA-2017-N-6502)
March 16, 2018 via online submission: www.regulations.gov The Honorable Scott Gottlieb Commissioner Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Opioid Policy Steering
More informationThe European Board of Urology
Page 1 of 15 The European Board of Urology Sub-specialty certification application: Prostate cancer, A - General information A1 - APPLICATION IDENTIFICATION 1a. Application code blank 1b. EBU internal
More informationNuclear Medicine Fact Sheet
Nuclear Medicine & Molecular Imaging Week PROMOTIONAL TOOLKIT October 5 11, s Nuclear Medicine Fact Sheet What is nuclear medicine? Nuclear medicine specialists use safe, painless, and cost-effective techniques
More informationMEDICAL POLICY SUBJECT: POSITRON EMISSION TOMOGRAPHY (PET) ONCOLOGIC APPLICATIONS. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY PAGE: 1 OF: 13 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationCRYOABLATION OF SOLID TUMORS
Status Active Medical and Behavioral Health Policy Section: Surgery Policy Number: IV-05 Effective Date: 06/16/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationElectrical Stimulation Device Used for Cancer Treatment
Electrical Stimulation Device Used for Cancer Treatment OPTUNE (NOVOTTF 100A SYSTEM) For any item to be covered by The Health Plan, it must: 1. Be eligible for a defined Medicare or The Health Plan benefit
More informationSustain and Seize Cancer Research Opportunities
One Voice Against Cancer (OVAC) appreciates the opportunity to submit written comments for the record regarding funding for cancer programs for research, prevention, detection, and treatment as well as
More informationDecember 18, Submitted Electronically
December 18, 2017 Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attn: CMS-4182-P PO Box 8013 Baltimore, MD 21244-8013 Submitted Electronically
More informationMolecular Imaging and Breast Cancer
Molecular Imaging and Breast Cancer Breast cancer forms in tissues of the breast usually in the ducts, tubes that carry milk to the nipple, and lobules, the glands that make milk. It occurs in both men
More informationCOVERAGE WITH EVIDENCE DEVELOPMENT
COVERAGE WITH EVIDENCE DEVELOPMENT OVERVIEW AND USE TO PROMOTE BIOMARKER DEVELOPMENT IOM National Cancer Policy Forum Sean Tunis, MD, MSc November 10, 2014 CED DEFINITION AND PURPOSE Reimbursement that
More informationColorectal cancer is the second most common cancer,
PET Changes and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study Andrew M. Scott 1,2, Dishan H. Gunawardana 1, Ben Kelley 3, John
More informationPET-CT in Oncology: an evidence based approach
Sarajavo (Bosnia & Hercegovina) Monday, June 16 2014 10:15-10:45 a.m PET-CT in Oncology: an evidence based approach Helle Westergren Hendel MD, PhD, assistant professor Bachelor in Leadership & Health
More informationDepartment of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, 2. College of Medicine, Iowa City, I
Variation in staging and treatment of rectal cancer by National Cancer Institute (NCI) designation and medical school affiliation: Analysis of Surveillance, Epidemiology 1 Department of Epidemiology, University
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationOriginal Policy Date
MP 6.01.17 Oncologic Applications of PET Scanning Medical Policy Section Radiology Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature/12:2013 Return to Medical
More informationCryosurgical Ablation of Breast Fibroadenomas
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationA Patient s Guide to SRS
A Patient s Guide to SRS Stereotactic Radiosurgery 230 Nebraska St. Sioux City, IA 51101 NOTES 230 Nebraska St. Sioux City, IA 51101 Contents page Introduction 1 SRS and how it works 2 The technology involved
More informationSetting The setting was outpatient (ambulatory patients). The economic study was carried out in France.
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Lejeune C, Bismuth M J, Conroy T, Zanni C, Bey P,
More informationLocal Coverage Determination for Hospice The Adult Failure To Thrive Syndrome (L31541)
Page 1 of 5 Centers for Medicare & Medicaid Services Print Message: If you are experiencing issues printing this page, then please click Return to Previous Page and select the 'Need a PDF?' button. You
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationLocal Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice)
Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice) Print Contractor Information Contractor Name Novitas Solutions, Inc. Contractor Numbers 04911, 07101, 07102, 07201,
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationClinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90
Clinical Policy: Reference Number: CP.MP.90 Effective Date: 01/18 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More information11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR
Outcomes Watching It Grow GATRA Annual Conference 2016 Lisa Connor, CTR The abstract begins after case finding The abstract is in progress The abstract is complete The abstract is revisited and nurtured
More informationAccess to Innovation Barriers and Solutions. Thomas D. Szucs
Access to Innovation Barriers and Solutions Thomas D. Szucs Gustave Courbet (1819-1877): Self Portrait or The Desperate Man 2 Nullum est iam dictum, quod non sit dictum prius. - Terenz 3 Put it before
More informationTitle: Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature
Author's response to reviews Title: Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature Authors: Haridimos Markogiannakis (markogiannakis@easy.com) Dimitrios
More informationCase Review of Inpatient Rehabilitation Hospital Patients Not Suited for Intensive Therapy
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES OFFICE OF INSPECTOR GENERAL Case Review of Inpatient Rehabilitation Hospital Patients Not Suited for Intensive Therapy OEI-06-16-00360 DECEMBER 2016 SUZANNE MURRIN
More informationCardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.
National Imaging Associates, Inc. Clinical guidelines CARDIOVASCULAR NUCLEAR MEDICINE -MYOCARDIAL PERFUSION IMAGING -MUGA CPT4 Codes: Refer to pages 6-9 LCD ID Number: L33960 J 15 = KY, OH Responsible
More information